Breast Cancer Information
More articles below:
Breast Cancer Risks Not Same for Hispanic Women
Remedy Needed for Overdiagnosis of Cancers
Black Women Wait Longer for Breast Cancer Diagnosis, Treatment
Studies Confirm Link Between Breast Density and Cancer
Steady Weight Gain Boosts Late-Life Breast Cancer Risk
Earlier Detection of Breast Cancer May Be Possible
Scientists Spot Clue to Cancer's Aggressiveness
TUESDAY, Sept. 8 (HealthDay News) -- Researchers say they have gained insight into whether certain aggressive cancers -- including those that attack the pancreas, breast and skin -- will respond to a certain anti-cancer drug.
The key appears to lie in a molecular signature inside tumors, researchers reported in the Sept. 6 online issue of Nature Medicine.
Researchers at the University of California, San Diego, found that a receptor on the surface of some tumor cells can start a process that leads cells to become more aggressive. An anti-cancer drug called dasatinib (Sprycel), approved for treating a form of leukemia, blocks the process.
Researchers say figuring out whether the receptor exists on tumor cells could indicate whether the tumors might respond to the drug.
"These results could enable us to identify the subpopulation of cancer patients who are likely to respond to treatment with dasatinib," study author David Cheresh, vice chair of pathology at the UC San Diego School of Medicine, said in a news release. "Rather than treat all patients with a given tumor type the same way, we can customize the treatment in such a way that we impact the patients most likely to be sensitive to a drug."
In pancreatic cancer, for example, about 60 percent of tumors appear to have the receptor, meaning they would be susceptible to the drug.
The next step is to design a clinical trial to test the theory.
More information
Learn more about cancer from the National Cancer Institute.
DON'T HAVE Rx COVERAGE?Click Here to print out your FREE OPTIMIZERx Card and instantly begin savings on your next prescriptions!
